Chemotherapy modulates intestinal immune gene expression in piglets including surfactant protein-D and DMBT1
Ontology highlight
ABSTRACT: Cytotoxic therapy leads to marked changes in intestinal structure, function, immunity and microbiota. Information about chemotherapy-induced intestinal gene expression may provide insights into the mechanisms underlying gut toxicity, and help to identify biomarkers and targets for intervention. We investigated jejunal tissue from piglets subjected to two different, clinically-relevant chemotherapy regimens, 1) busulfan plus cyclophosphamide (BUCY) and 2) doxorubicin (DOX). Gene expression analysis identified 1328 and 594 differentially expressed genes in the BUCY and DOX pigs, compared with their respective controls. Similar changes in expression patterns across BUCY and DOX piglets were found for 137 genes (95 genes repressed and 42 induced). Selected genes of potential biological significance were confirmed by real-time polymerase chain reaction. Key innate defense molecules, including surfactant protein-D (SP-D), deleted in malignant brain tumors 1 (DMBT-1) and peptidoglycan recognition protein 2 (PGLYRP2) were among the up-regulated genes for both chemotherapy treatments. Based on the results from the two different treatments, we conclude that chemotherapy induces reduced intestinal adaptive immunity while innate immune functions involved in surveillance, protection and homeostasis of mucosal surfaces are up-regulated. The results may be of value to understand monitor and prevent chemotherapy-induced intestinal mucositis by dietary or medical interventions.
ORGANISM(S): Sus scrofa
PROVIDER: GSE71964 | GEO | 2018/07/01
REPOSITORIES: GEO
ACCESS DATA